TICKERNERD
Menu
ENLVENLVHealthcare · Biotechnology

ENLV Stock Forecast: Enlivex Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.48
−1.33% on the day

The 1 Wall Street analysts covering Enlivex Ltd. hold a median 12-month price target of $80 — +5305.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$25.7M
Ticker Nerd rank
31 / 100
Median analyst target
$80
Analysts covering
1
Total return, dividends reinvested
1W
−6.3%
1M
−68.7%
YTD
−86.0%
1Y
−90.4%
From 52W high
−91.8%
From 52W low
0.0%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enlivex Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
31 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Quality
85
Volatility
63
Growth
59
Revisions
54
Issuance
18
Value
18
Accruals
13
Momentum
4

Size (87): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26ENLVHigh $80Median $80Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $80Median $80High $80

The green dot is the last close — the median target sits +5305.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $80
7 Apr 2026HC Wainwright & Co.MaintainsBuy$13 → $20
7 Apr 2026HC Wainwright & Co.MaintainsBuy—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
24 Nov 2025D. Boral CapitalDowngradeHold—
29 Oct 2025D. Boral CapitalMaintainsBuy—
26 Sept 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025D. Boral CapitalMaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
22 July 2025D. Boral CapitalMaintainsBuy—
21 Apr 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025D. Boral CapitalMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
3 Mar 2025D. Boral CapitalMaintainsBuy—
7 Feb 2025D. Boral CapitalMaintainsBuy—
11 Dec 2024D. Boral CapitalMaintainsBuy—
3 Dec 2024D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENLV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ENLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Enlivex Ltd. (ENLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
−1.2×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
126.2%

Higher than 97% of US stocks

Return on assets
−0.8%

Higher than 40% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ENLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENLVEnlivex Ltd.$25.7M
31
TVRDTvardi Therapeutics, Inc.$24.8M
28
CVMCEL-SCI Corp.$24.8M
34
CLRBCellectar Biosciences, Inc.$24.5M
25
GRDXGridAI Technologies Corp.$25.3M
38
ATOSAtossa Therapeutics, Inc.$25.3M
23
JSPRJasper Therapeutics, Inc.$23.8M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enlivex Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENLV news & analysis

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

GlobeNewsWire · 30 July 2026positive

Enlivex reported that trading volume on its Rain protocol reached $860 million as of July 29, 2026, representing 622% month-over-month growth in July compared to June.

Why it matters — The Rain protocol's trading metrics are part of Enlivex's treasury portfolio, so volume growth is directly relevant to the company's financial performance and valuation.

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

GlobeNewsWire · 29 July 2026positive

Enlivex announced that its management will host a live webinar on July 30, 2026 to discuss the company's private placement, Rain Protocol treasury strategy, and recent clinical progress for Allocetra™ including a new RMAT designation from the FDA.

Why it matters — The webinar will provide ENLV watchers with additional detail on the company's capital strategy, treasury strategy, and recent clinical milestones for Allocetra™.

Enlivex Announces $400,000,000 Private Placement

GlobeNewsWire · 28 July 2026positive

Enlivex announced a private placement of $400,000,000 of ordinary shares with a single institutional investor, at a per-share price of $5.00 for dollar-denominated subscriptions or $6.00 for subscriptions funded in RAIN tokens. The investor has elected to fund the purchase using RAIN tokens, with the option to change this election before closing.

Why it matters — The large capital raise provides Enlivex with substantial funding to execute its treasury strategy built around the Rain protocol while continuing to advance its clinical-stage immunotherapy Allocetra™.

FAQ

Frequently asked questions about ENLV stock

What is the ENLV stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Enlivex Ltd. have a median 12-month price target of $80, with estimates ranging from $80 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENLV stock a buy right now?

Of the 1 analysts covering Enlivex Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enlivex Ltd. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENLV?

As at 22 Aug 2026, Enlivex Ltd. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will ENLV stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +5305.4% from the last close, and Ticker Nerd's factor model ranks Enlivex Ltd. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENLV stock forecast for 2030?

No analyst covering Enlivex Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $80 over the next 12 months.

How has ENLV stock performed over the past year?

Enlivex Ltd. returned -90.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enlivex Ltd. do?

Enlivex Ltd. is a clinical-stage macrophage reprogramming immunotherapy company headquartered in Ness Ziona, Israel.

What is the latest news on ENLV?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June". Enlivex reported that trading volume on its Rain protocol reached $860 million as of July 29, 2026, representing 622% month-over-month growth in July compared to June.

Company

About Enlivex Ltd.

Enlivex Ltd. is a clinical-stage macrophage reprogramming immunotherapy company headquartered in Ness Ziona, Israel. The company focuses on the late-stage clinical development of Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages, key immune cells, back into their homeostatic state for the treatment of inflammatory and age-related diseases. Currently, Enlivex concentrates on osteoarthritis, particularly age-related knee osteoarthritis, aiming to address pain, function, and quality-of-life limitations through immune rebalancing rather than purely symptomatic relief. In parallel, Enlivex manages a substantial digital asset treasury centered on the Rain prediction markets protocol, creating a differentiated profile that combines a biotechnology platform with exposure to decentralized prediction market infrastructure. This dual structure positions Enlivex as an unusual participant at the intersection of healthcare and digital-asset-driven treasury management, with relevance to both the immunotherapy and prediction markets ecosystems.

34 employees · Israel · https://www.enlivex.com